NuCana publishes corporate presentation on ProTide-based oncology pipeline
NCNA•Corporate presentation highlights lead program and clinical data
NuCana highlighted NUC-7738 as its lead oncology program, positioning it to improve responses to PD-(L)1 inhibitors in resistant tumors.
- NuTide:701 monotherapy data showed a 41% disease control rate in efficacy-evaluable patients, with no Grade 4 toxicities reported.
- Combination dosing in melanoma paired NUC-7738 with pembrolizumab, with tumor reductions of 55% and 32% cited in heavily pretreated patients.
- Cash and cash equivalents were about USD 28.4 million as of March 31, 2026, with runway projected into 2029.
